Genor Bio Conducting $370 Million IPO in Hong Kong

Genor Biopharma, a Shanghai company, is conducting a Hong Kong IPO that could raise up to $370 million. The company is developing a clinical-stage portfolio of 14 mAbs and recombinant fusion proteins, a combination of novel drugs and biosimilars that target indications in cancer, metabolic and autoimmune diseases. Its PD-1 molecule is currently in four pivotal Phase II trials. In June, Genor completed a $160 million Series B financing led by Beijing's Hillhouse Capital Group. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.